Background
Globally, prostate cancer (PCa) is the second most common malignancy in men. With an estimated 1 million new cases in 2018, it has now become the 5th leading cause of cancer death worldwide [
1]. Due to the widespread use of serum prostate specific antigen (PSA) testing and extended prostate biopsy techniques, PCa is usually detected at an earlier stage. Hence, tumours tend to have more favourable clinical characteristics and long-term survival outcomes [
2]. This has led to the rapid evolution and acceptance of active surveillance (AS) treatment for low and intermediate-risk PCa.
Previously, men with localized PCa would have undergone radical removal of the whole prostate gland leading to a high rate of overtreatment of clinically insignificant PCa (suggested to be as high as 56%) [
3]. AS enables close monitoring under an organised regime of PSA testing, biopsies and/or magnetic resonance imaging (MRI) that allows patients to be regularly observed for signs of disease progression, indicating the need for active treatment rather than commencing radical therapy immediately [
4]. From a medical perspective, the benefit and effectiveness of AS is well documented [
5,
6], and AS has the potential to provide fewer physical symptoms than a radical prostatectomy such as sexual and urinary function symptoms [
7]. However, recently more studies have focused on the effects on mental health and well-being throughout the process, especially during biopsies. Uncertainty that arises when living with an untreated cancer has the potential to cause significant emotional burden, increasing a patient’s anxiety [
8]. A clear need for a less invasive monitoring approach is highlighting the potential increase in use of MRI instead of biopsies as a PCa diagnostic and monitoring test [
9].
While generally accepted as a suitable management option for low risk PCa, AS monitoring regime vary among clinical practices and guidelines, leading to it being questioned by some clinicians and patients [
10]. In effort to minimise this, the Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) which has combined data from AS cohorts worldwide to create a global consensus for selection, monitoring and treatment intervention thresholds [
11]. Most AS protocols at UK centres are based upon NICE and EAU guidelines [
12,
13], however current clinical practices at UK centres vary from these guidelines [
7]. While Kinsella et al. [
5] documents protocols for several published AS cohorts, practices at GSTT are yet to be described in detail. With a relatively long follow up and ethnically diverse patient population, the GSTT AS cohort (GSTT-AS) is now one of the largest participating UK centres within the GAP3 initiative [
14]. Monitoring AS cohorts provides an avenue to explore differences between other global surveillance protocols, helping identify standards that define the best surveillance approach for better patient outcomes.
This study profiles the GSTT-AS, part of the wider GAP3 initiative, by characterizing patients undergoing surveillance, follow-up procedures and trends in patient outcomes. Additionally, it aims to identify possible predictive factors for converting to active treatment, and highlights changes in practices over time.
Utility and discussion
With focus on baseline characteristics, details of follow-up, clinical outcomes and changes in practice over time, our cohort description has identified some specific characteristics that make the GSTT-AS a useful resource for clinical research focused on AS for PCa.
It is interesting to note that there was a relatively large proportion of men of African/Afro-Caribbean descent. This may in part explain the inclusion of some men with higher PSA levels in the GSTT AS cohort, given that high PSA levels at diagnosis have been observed among Black African/Caribbean men previously [
15,
16]. The diversity of the GSTT cohort provides opportunities to explore variations in AS patient pathway and their outcomes according to ethnicity. However, our results showed no significant difference in the risk of conversion to treatment in different ethnic groups. Beckmann et al. explored this further and investigated protocol adherence and outcomes among African/Afro-Caribbean males at GSTT [
17]. Similar findings were observed and the need for a more tailored program with careful monitoring for this cohort of men was indicated. Our cohort also includes men who fall outside NICE and EAU guidelines for AS eligibility, including 12% with PSA > 10 ng/ml and 15% with more than three positive cores at diagnosis [
12,
18]. Whilst men with PSA > 10 ng/ml do not appear to have increased risk of converting to treatment, the latter may be at greater risk of progressing to treatment and therefore reflecting the greater use of TP biopsy and MRI for men enrolled in AS in more recent years.
At GSTT, men diagnosed after 2012 were more likely to receive MRI scans at diagnosis (51.7% of men > 2012 in vs. 14.0% < 2012). In 2015, NICE released a guideline encouraging the use of an early mpMRI for the initial assessment of candidates for AS, however GSTT protocols adopted the use of MRI in diagnosis and follow-up earlier, through the evidence and guidelines available circa 2012. The European Society of Urogenital Radiology (ESUR) published guidelines for mpMRI in 2012 and stated that a TRUS biopsy underestimates the extent and grade of PCa [
19]. PROMIS (PROstate MRI Imaging Study) also found that mpMRI has the potential to outperform the accuracy of a TRUS biopsy in PCa diagnosis [
9]. When TRUS biopsies were then guided by mpMRI findings, an increase of 18% in the detection of clinically significant cancers was observed [
9]. The release of the ESUR guidelines, plus the trial evidence indicating the benefits of MRI may be the reason for more patients at GSTT having MRI at diagnosis after 2012. Further research is required to assess whether early adoption of MRI within the GSTT AS protocol has led to more accurate diagnoses of clinically significant and insignificant PCa resulting in better selection of men for AS.
Increased use of a TP diagnostic biopsy since 2012 at GSTT was observed (39.2% > 2012 vs. 33.6% < 2012,
p = 0.12). Whilst NICE guidance acknowledges the different biopsy techniques available, data on the outcomes of TRUS diagnostic biopsy are more widely available and so remain the recommended diagnostic biopsy method [
12]. However, determining the most beneficial biopsy method is a controversial topic in current literature. Studies comparing TRUS and TP detection and complication rates remain inconclusive [
20,
21], though the recent meta-analysis by Xiang et al. found that both methods had similar diagnostic efficacy but that TP biopsy was associated with a significant decrease in infection and rectal bleeding [
22]. Historically, TP biopsy required the use of general anaesthetic and extensive histological analysis, however researchers at GSTT have recently investigated the outcomes of the PrecisionPoint™ access system (Perineologic, Cumberland, MD, USA) for freehand TP biopsies which are less resource intensive than conventional TP biopsies as they can be carried out under local anaesthetic [
22]. Two distinct pathways of AS follow-up can also be seen within the GSTT-AS. When diagnosed using a TRUS biopsy, median time to the first biopsy was 6 months with 63% of men having the first biopsy within the first year. Men who underwent TP diagnostic biopsy received their first follow-up biopsy much later (median = 26 months) with only 19% having been biopsied within the first year of AS. These findings are in line with current GSTT AS protocols which recommend a confirmatory TP biopsy at 6 months for men initially diagnosed via TRUS biopsy, many of which have been referred to GSTT from other centres. Future directions of this research involve a longer patient follow-up and an assessment of the cost effectiveness of TP biopsy under local anaesthetic vs the gold standard TRUS biopsy.
The differences in the median time to the first MRI (45 months) and first biopsy (13 months) during follow-up at GSTT show that some patients underwent biopsies without a previous MRI. Due to the non-invasive nature, MRI has sparked interest in its serial use during follow-up of men on AS in many healthcare systems and from 2014, NICE guidelines encouraged the use of mpMRI as part of AS follow-up to detect disease progression and drive repeat biopsies [
12]. However findings in studies investigating the role of serial MRI for AS monitoring are contradictory [
23‐
25]. The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) panel have developed recommendations in effort to highlight clearer thresholds identifying radiologically significant disease progression [
26]. Since GSTT-AS spans diagnoses from 2002 onwards, many of the cohort would have been monitored before MRI-guided biopsy became a recommended part of follow-up, with our results reflecting changes to the GSTT protocol over time. Further investigations with longer follow-up of patients enrolled after MRI was incorporated into the GSTT AS protocol are required to assess its benefits.
In line with the findings from Royal Marsden and Toronto cohort, our cohort shows GS of 3 + 4 to be highly predictive for progressing to treatment (HR: 2.41 CI: 1.79–3.26) when compared with GS 3 + 3 [
27,
28]. However, many of the patients in older studies, such as the Toronto cohort, were graded using an older version of the Gleason grading system (1996–2005). Re-grading was not performed resulting in different stratification of low and intermediate risk groups with many of the patients graded GS 6 possibly being re-graded to GS 3 + 4 using the modified Gleason system [
29]. Currently, the suitability of men with GS 3 + 4 for AS is still debated [
30,
31]. GSTT-AS only contains a small number of patients diagnosed before 2006 and hence the majority are classified according to more updated versions of Gleason grading criteria [
29] making it a useful resource for the scientific community for further research to refine GS threshold for entry onto active surveillance.
A significant increased risk of progression to treatment in GSTT-AS was observed for patients with more than two positive cores compared with one positive core as has been observed in other cohorts [
27,
31]. Whilst the number of positive cores has been described to be a positive predictor for progression to treatment, the pathway for patients with a negative biopsy on follow-up is unclear. Using data from GSTT-AS our team has recently investigated the possibility of modifying AS protocols for men with negative findings on prostate re-biopsy [
32].
Our finding of lower risk of conversion to active treatment among patients diagnosed after 2012 translates into fewer men converting to radical treatment, hence less potential for side effects such as urinary incontinence and erectile dysfunction [
13]. This finding could indicate better selection of candidates for AS at entry can lead to better outcomes and therefore supports the rationale behind the GSTT protocol since 2012, with its increased use of MRI scans and TP biopsy at diagnosis, and the increased number of cores taken. Verification that these strategies decrease the risk of conversion to treatment in the longer term requires further investigation, ideally in a trial setting [
33].
Limitations
The data collection was mainly retrospective which allows for the introduction of selection and information bias. During the initial start-up of GSTT-AS not all AS patients were enrolled, resulting in interrupted patient selection. Given the nature of the cohort, only the information available in the patient record can be retrieved limiting the collection of information on confounders such as BMI and comorbidities. Data collected on imaging methods during follow-up should be a focus of ongoing and future studies. Efforts should be made to establish prospective data collection so that up-to-date information can be shared with researchers and clinicians to help guide the AS management strategy.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.